Kineta, Inc. (KA)
- Previous Close
0.6200 - Open
0.6094 - Bid 0.5971 x 500
- Ask 0.6457 x 500
- Day's Range
0.5700 - 0.6500 - 52 Week Range
0.3340 - 5.3900 - Volume
182,404 - Avg. Volume
378,720 - Market Cap (intraday)
7.014M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2800 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
13.50
Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.
kinetabio.comRecent News: KA
Performance Overview: KA
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KA
Valuation Measures
Market Cap
7.01M
Enterprise Value
2.55M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.30
Price/Book (mrq)
2.43
Enterprise Value/Revenue
0.47
Enterprise Value/EBITDA
-0.19
Financial Highlights
Profitability and Income Statement
Profit Margin
-259.08%
Return on Assets (ttm)
-70.91%
Return on Equity (ttm)
-369.01%
Revenue (ttm)
5.44M
Net Income Avi to Common (ttm)
-14.1M
Diluted EPS (ttm)
-1.2800
Balance Sheet and Cash Flow
Total Cash (mrq)
5.78M
Total Debt/Equity (mrq)
43.05%
Levered Free Cash Flow (ttm)
-10.42M
Research Analysis: KA
Company Insights: KA
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: KA
Daily – Vickers Top Insider Picks for 12/20/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 12/19/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 12/18/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 12/15/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.